Extracellular matrix, gap junctions, and retinal vascular homeostasis in diabetic retinopathy

Experimental Eye Research

Volumn 133, Issue , 2015, Pages 58-68

  Roy, Sayon ^a   Bae, Edward ^a   Amin, Shruti ^a   Kim, Dongjoon ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basement membrane; Collagen type IV; Connexin; Diabetic retinopathy; Extracellular matrix; Fibronectin; Gap junction; Laminin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AGRIN; ALDEHYDE REDUCTASE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; ENTACTIN; FIBRONECTIN; GELATINASE A; GELATINASE B; GLUCOSE; INTEGRIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LAMININ; MONOCYTE CHEMOTACTIC PROTEIN 1; PERLECAN; PROTEIN KINASE C BETA; PROTEOHEPARAN SULFATE; REACTIVE OXYGEN METABOLITE; TENASCIN; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; ASTROCYTE; BASEMENT MEMBRANE; BLOOD VESSEL PERMEABILITY; CELL COMMUNICATION; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GAP JUNCTION; GENE CONTROL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INFLAMMATION; MUELLER CELL; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RETINA CAPILLARY; RETINAL VASCULAR HOMEOSTASIS; REVIEW; UPREGULATION; VISUAL IMPAIRMENT; METABOLISM; PATHOLOGY; RETINA BLOOD VESSEL;

DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; GAP JUNCTIONS; HOMEOSTASIS; HUMANS; RETINAL VESSELS;

EID: 84925435002     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.08.011     Document Type: Review

References (155)

1. Abari E., Kociok N., Hartmann U., Semkova I., Paulsson M., Lo A., Joussen A.M. Alterations in basement membrane immunoreactivity of the diabetic retina in three diabetic mouse models. Graefe's Arch. Clin. Exp. Ophthalmol. Albrecht von Graefes Arch. klin. Exp. Ophthalmol. 2013, 251:763-775.
2. Aumailley M., Battaglia C., Mayer U., Reinhardt D., Nischt R., Timpl R., Fox J.W. Nidogen mediates the formation of ternary complexes of basement membrane components. Kidney Int. 1993, 43:7-12.
3. Aumailley M., Bruckner-Tuderman L., Carter W.G., Deutzmann R., Edgar D., Ekblom P., Engel J., Engvall E., Hohenester E., Jones J.C., Kleinman H.K., Marinkovich M.P., Martin G.R., Mayer U., Meneguzzi G., Miner J.H., Miyazaki K., Patarroyo M., Paulsson M., Quaranta V., Sanes J.R., Sasaki T., Sekiguchi K., Sorokin L.M., Talts J.F., Tryggvason K., Uitto J., Virtanen I., von der Mark K., Wewer U.M., Yamada Y., Yurchenco P.D. Asimplified laminin nomenclature. Matrix Biol. J. Int. Soc. Matrix Biol. 2005, 24:326-332.
4. Behl Y., Krothapalli P., Desta T., DiPiazza A., Roy S., Graves D.T. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol. 2008, 172:1411-1418.
5. Behl Y., Krothapalli P., Desta T., Roy S., Graves D.T. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes 2009, 58:917-925.
6. Bhattacharjee P.S., Huq T.S., Potter V., Young A., Davenport I.R., Graves R., Mandal T.K., Clement C., McFerrin H.E., Muniruzzaman S., Ireland S.K., Hill J.M. High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E. PloS One 2012, 7:e52152.
7. Bobbie M.W., Roy S., Trudeau K., Munger S.J., Simon A.M., Roy S. Reduced connexin 43 expression and its effect on the development of vascular lesions in retinas of diabetic mice. Investig. Ophthalmol. Vis. Sci. 2010, 51:3758-3763.
8. Boudreau N.J., Jones P.L. Extracellular matrix and integrin signalling: the shape of things to come. Biochem. J. 1999, 339(Pt 3):481-488.
9. Budak Y., Demirci H., Akdogan M., Yavuz D. Erytrocyte membrane anionic charge in type 2 diabetic patients with retinopathy. BMC Ophthalmol. 2004, 4:14.
10. Bystrom B., Virtanen I., Rousselle P., Gullberg D., Pedrosa-Domellof F. Distribution of laminins in the developing human eye. Investig. Ophthalmol. Vis. Sci. 2006, 47:777-785.
11. Castellon R., Caballero S., Hamdi H.K., Atilano S.R., Aoki A.M., Tarnuzzer R.W., Kenney M.C., Grant M.B., Ljubimov A.V. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Investig. Ophthalmol. Vis. Sci. 2002, 43:2758-2766.
12. Chen S., Mukherjee S., Chakraborty C., Chakrabarti S. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am. J. Physiol. Cell Physiol. 2003, 284:C263-C272.
13. Cherian S., Roy S., Pinheiro A., Roy S. Tight glycemic control regulates fibronectin expression and basement membrane thickening in retinal and glomerular capillaries of diabetic rats. Investig. Ophthalmol. Vis. Sci. 2009, 50:943-949.
14. Chronopoulos A., Tang A., Beglova E., Trackman P.C., Roy S. High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function. Diabetes 2010, 59:3159-3166.
15. Chronopoulos A., Trudeau K., Roy S., Huang H., Vinores S.A., Roy S. High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Curr. Eye Res. 2011, 36:747-753.
16. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.-Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J.Biol. Chem. 1996, 271:736-741.
17. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab. Res. Rev. 2001, 17:412-421.
18. Costa P.Z., Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci. 2013, 92:1037-1045.
19. Crossin K.L. Tenascin: a multifunctional extracellular matrix protein with a restricted distribution in development and disease. J.Cell. Biochem. 1996, 61:592-598.
20. Cybulsky A.V., Carbonetto S., Cyr M.D., McTavish A.J., Huang Q. Extracellular matrix-stimulated phospholipase activation is mediated by beta 1-integrin. Am. J. Physiol. 1993, 264:C323-C332.
21. Czyz J., Guan K., Zeng Q., Wobus A.M. Loss of beta 1 integrin function results in upregulation of connexin expression in embryonic stem cell-derived cardiomyocytes. Int. J. Dev. Biol. 2005, 49:33-41.
22. Dagli M.L., Hernandez-Blazquez F.J. Roles of gap junctions and connexins in non-neoplastic pathological processes in which cell proliferation is involved. J.Membr. Biol. 2007, 218:79-91.
23. Das A., McGuire P.G. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog. Retin. Eye Res. 2003, 22:721-748.
24. Davis J.T., Wen Q., Janmey P.A., Otteson D.C., Foster W.J. Muller cell expression of genes implicated in proliferative vitreoretinopathy is influenced by substrate elastic modulus. Investig. Ophthalmol. Vis. Sci. 2012, 53:3014-3019.
25. Dolz R., Engel J., Kuhn K. Folding of collagen IV. Eur. J. Biochem. FEBS 1988, 178:357-366.
26. Durham J.T., Herman I.M. Microvascular modifications in diabetic retinopathy. Curr. Diabetes Rep. 2011, 11:253-264.
27. El-Sabban M.E., Sfeir A.J., Daher M.H., Kalaany N.Y., Bassam R.A., Talhouk R.S. ECM-induced gap junctional communication enhances mammary epithelial cell differentiation. J.Cell Sci. 2003, 116:3531-3541.
28. Eming S.A., Hubbell J.A. Extracellular matrix in angiogenesis: dynamic structures with translational potential. Exp. Dermatol. 2011, 20:605-613.
29. Engerman R.L., Kern T.S. Hyperglycemia and development of glomerular pathology: diabetes compared with galactosemia. Kidney Int. 1989, 36:41-45.
30. Engerman R.L., Kern T.S. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 1993, 42:820-825.
31. Feenstra D.J., Yego E.C., Mohr S. Modes of retinal cell death in diabetic retinopathy. J.Clin. Exp. Ophthalmol. 2013, 4:298.
32. Feng B., Cao Y., Chen S., Ruiz M., Chakrabarti S. miRNA-1 regulates endothelin-1 in diabetes. Life Sci. 2014, 98:18-23.
33. Fernandes R., Girao H., Pereira P. High glucose down-regulates intercellular communication in retinal endothelial cells by enhancing degradation of connexin 43 by a proteasome-dependent mechanism. J.Biol. Chem. 2004, 279:27219-27224.
34. Gardiner T.A., Anderson H.R., Stitt A.W. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J.Pathol. 2003, 201:328-333.
35. Geraldes P., King G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res. 2010, 106:1319-1331.
36. Gerhardinger C., Dagher Z., Sebastiani P., Park Y.S., Lorenzi M. The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 2009, 58:1659-1667.
37. George B., Chen S., Chaudhary V., Gonder J., Chakrabarti S. Extracellular matrix proteins in epiretinal membranes and in diabetic retinopathy. Curr. Eye Res. 2009, 34:134-144.
38. Gogula S.V., Divakar C., Satyanarayana C., Kumar Y.P., Lavanaya V.S. Computational investigation of pkcbeta inhibitors for the treatment of diabetic retinopathy. Bioinformation 2013, 9:1040-1043.
39. Goodwin A.M., Kitajewski J., D'Amore P.A. Wnt1 and Wnt5a affect endothelial proliferation and capillary length; Wnt2 does not. Growth Factors 2007, 25:25-32.
40. Hamelin R., Allagnat F., Haefliger J.A., Meda P. Connexins, diabetes and the metabolic syndrome. Curr. Protein Pept. Sci. 2009, 10:18-29.
41. Han J., Zhang F., Xie J., Linhardt R.J., Hiebert L.M. Changes in cultured endothelial cell glycosaminoglycans under hyperglycemic conditions and the effect of insulin and heparin. Cardiovasc. Diabetol. 2009, 8:46.
42. Han S.Y., Kang Y.S., Jee Y.H., Han K.H., Cha D.R., Kang S.W., Han D.S. High glucose and angiotensin II increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Cell Tissue Res. 2006, 323:321-332.
43. Houck K.A., Leung D.W., Rowland A.M., Winer J., Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J.Biol. Chem. 1992, 267:26031-26037.
44. Hsieh H.L., Chi P.L., Lin C.C., Yang C.C., Yang C.M. Up-regulation of ROS-dependent matrix metalloproteinase-9 from high-glucose-challenged astrocytes contributes to the neuronal apoptosis. Mol. Neurobiol. 2014.
45. Huet C., Monget P., Pisselet C., Hennequet C., Locatelli A., Monniaux D. Chronology of events accompanying follicular atresia in hypophysectomized ewes. Changes in levels of steroidogenic enzymes, connexin 43, insulin-like growth factor II/mannose 6 phosphate receptor, extracellular matrix components, and matrix metalloproteinases. Biol. Reprod. 1998, 58:175-185.
46. Inoguchi T., Yu H.Y., Imamura M., Kakimoto M., Kuroki T., Maruyama T., Nawata H. Altered gap junction activity in cardiovascular tissues of diabetes. Med. Electron Microsc. Off. J. Clin. Electron Microsc. Soc. Jpn. 2001, 34:86-91.
47. Isakson B.E., Olsen C.E., Boitano S. Laminin-332 alters connexin profile, dye coupling and intercellular Ca2+ waves in ciliated tracheal epithelial cells. Respir. Res. 2006, 7:105.
48. Joussen A.M., Doehmen S., Le M.L., Koizumi K., Radetzky S., Krohne T.U., Poulaki V., Semkova I., Kociok N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 2009, 15:1418-1428.
49. Kador P.F., Randazzo J., Blessing K., Makita J., Zhang P., Yu K., Hosoya K., Terasaki T. Polyol formation in cell lines of rat retinal capillary pericytes and endothelial cells (TR-rPCT and TR-iBRB). J.Ocular Pharmacol. Ther. Off. J. Assoc. Ocular Pharmacol. Ther. 2009, 25:299-308.
50. Kandarakis S.A., Piperi C., Topouzis F., Papavassiliou A.G. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog. Retin. Eye Res. 2014, 42:85-102.
51. Kotajima N., Kanda T., Yuuki N., Kimura T., Kishi S., Fukumura Y., Tamura I., Kobayashi I. Type IV collagen serum and vitreous fluid levels in patients with diabetic retinopathy. J. Int. Med. Res. 2001, 29:292-296.
52. Kowluru R.A., Zhong Q., Santos J.M. Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin. Investig. Drugs 2012, 21:797-805.
53. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., King G.L. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J.Clin. Investig. 1997, 100:115-126.
54. Kuiper E.J., Hughes J.M., Van Geest R.J., Vogels I.M., Goldschmeding R., Van Noorden C.J., Schlingemann R.O., Klaassen I. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Investig. Ophthalmol. Vis. Sci. 2007, 48:4267-4276.
55. Kuiper E.J., Witmer A.N., Klaassen I., Oliver N., Goldschmeding R., Schlingemann R.O. Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. Br. J. Ophthalmol. 2004, 88:1082-1087.
56. Lakka S.S., Gondi C.S., Dinh D.H., Olivero W.C., Gujrati M., Rao V.H., Sioka C., Rao J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J.Biol. Chem. 2005, 280:21882-21892.
57. Le Gat L., Gogat K., Bouquet C., Saint-Geniez M., Darland D., Van Den Berghe L., Marchant D., Provost A., Perricaudet M., Menasche M., Abitbol M. Invivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther. 2003, 10:2098-2103.
58. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J.Cell Biol. 2005, 169:681-691.
59. Lee S., Zeiger A., Maloney J.M., Kotecki M., Vliet K.J.V., Herman I.M. Pericyte actomyosin-mediated contraction at the cell-material interface can modulate the microvascular niche. J.Phys. Condens. Matter 2010, 22:194115.
60. Lee S.E., Ma W., Rattigan E.M., Aleshin A., Chen L., Johnson L.L., D'Agati V.D., Schmidt A.M., Barile G.R. Ultrastructural features of retinal capillary basement membrane thickening in diabetic swine. Ultrastruct. Pathol. 2010, 34:35-41.
61. Lenselink E.A. Role of fibronectin in normal wound healing. Int. Wound J. 2013.
62. Li A.F., Roy S. High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. Investig. Ophthalmol. Vis. Sci. 2009, 50:1400-1407.
63. Li A.F., Sato T., Haimovici R., Okamoto T., Roy S. High glucose alters connexin 43 expression and gap junction intercellular communication activity in retinal pericytes. Investig. Ophthalmol. Vis. Sci. 2003, 44:5376-5382.
64. Li M.W., Mruk D.D., Cheng C.Y. Gap junctions and blood-tissue barriers. Adv. Exp. Med. Biol. 2012, 763:260-280.
65. Lin C.L., Wang J.Y., Huang Y.T., Kuo Y.H., Surendran K., Wang F.S. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J.Am. Soc. Nephrol. JASN 2006, 17:2812-2820.
66. Lin F.L., Chang C.I., Chuang K.P., Wang C.Y., Liu H.J. Advanced glycation end products down-regulate gap junctions in human hepatoma SKHep 1 cells via the activation of Src-dependent ERK1/2 and JNK/SAPK/AP1 signaling pathways. J.Agric. Food Chem. 2010, 58:8636-8642.
67. Liu X., Ye F., Xiong H., Hu D., Limb G.A., Xie T., Peng L., Yang W., Sun Y., Zhou M., Song E., Zhang D.Y. IL-1beta upregulates IL-8 production in human muller cells through activation of the p38 MAPK and ERK1/2 signaling pathways. Inflammation 2014.
68. Ljubimov A.V., Burgeson R.E., Butkowski R.J., Couchman J.R., Zardi L., Ninomiya Y., Sado Y., Huang Z.S., Nesburn A.B., Kenney M.C. Basement membrane abnormalities in human eyes with diabetic retinopathy. J.Histochem. Cytochem. Off. J. Histochem. Soc. 1996, 44:1469-1479.
69. Ly A., Yee P., Vessey K.A., Phipps J.A., Jobling A.I., Fletcher E.L. Early inner retinal astrocyte dysfunction during diabetes and development of hypoxia, retinal stress, and neuronal functional loss. Investig. Ophthalmol. Vis. Sci. 2011, 52:9316-9326.
70. Makino H., Yamasaki Y., Haramoto T., Shikata K., Hironaka K., Ota Z., Kanwar Y.S. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab. Investig. J. Tech. Methods Pathol. 1993, 68:45-55.
71. Manasson J., Tien T., Moore C., Kumar N.M., Roy S. High glucose-induced downregulation of connexin 30.2 promotes retinal vascular lesions: implications for diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2013, 54:2361-2366.
72. Mao Y., Schwarzbauer J.E. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol. J. Int. Soc. Matrix Biol. 2005, 24:389-399.
73. Marneros A.G., Olsen B.R. Physiological role of collagen XVIII and endostatin. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2005, 19:716-728.
74. Miyata Y., Kase M., Sugita Y., Shimada A., Nagase T., Katsura Y., Kosano H. Protein kinase C-mediated regulation of matrix metalloproteinase and tissue inhibitor of metalloproteinase production in a human retinal muller cells. Curr. Eye Res. 2012, 37:842-849.
75. Mohammad G., Kowluru R.A. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2011, 52:3832-3841.
76. Mohammad G., Mairaj Siddiquei M., Imtiaz Nawaz M., Abu El-Asrar A.M. The ERK1/2 inhibitor U0126 attenuates diabetes-induced upregulation of MMP-9 and biomarkers of inflammation in the retina. J.Diabetes Res. 2013, 2013:658548.
77. Mohammad G., Siddiquei M.M. Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy. J.Ocular Biol. Dis. Inform. 2012, 5:1-8.
78. Moon J., Knack H.P., Roy S. Effect of inhibiting high glucose-induced upregulation of ECM on connexin 43 (Cx43) expression in retinal endothelial cells. Investig. Ophthalmol. Vis. Sci. 2011, 52. ARVO 2011 Conference, E-Abstract 3554.
79. Mori R., Power K.T., Wang C.M., Martin P., Becker D.L. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J.Cell Sci. 2006, 119:5193-5203.
80. Muto T., Tien T., Kim D., Sarthy V.P., Roy S. High glucose alters cx43 expression and gap junction intercellular communication in retinal muller cells: promotes muller cell and pericyte apoptosis. Investig. Ophthalmol. Vis. Sci. 2014, 55:4327-4337.
81. Nakahara M., Miyata K., Otani S., Miyai T., Nejima R., Yamagami S., Amano S. Arandomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients. Br. J. Ophthalmol. 2005, 89:266-268.
82. Nakamura T., Takahashi T., Fukui M., Ebihara I., Osada S., Tomino Y., Koide H. Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J.Am. Soc. Nephrol. JASN 1995, 5:1492-1497.
83. Nehmé A., Edelman J. Dexamethasone inhibits high glucose-, TNF-α-, and IL-1β-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Investig. Ophthalmol. Vis. Sci. 2008, 49:2030-2038.
84. Nishiguchi K.M., Ushida H., Tomida D., Kachi S., Kondo M., Terasaki H. Age-dependent alteration of intraocular soluble heparan sulfate levels and its implications for proliferative diabetic retinopathy. Mol. Vis. 2013, 19:1125-1131.
85. Ockleford C., Bright N., Hubbard A., D'Lacey C., Smith J., Gardiner L., Sheikh T., Albentosa M., Turtle K. Micro-trabeculae, macro-plaques or mini-basement membranes in human term fetal membranes?. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 1993, 342:121-136.
86. Oloris S.C., Mesnil M., Reis V.N., Sakai M., Matsuzaki P., Fonseca Ede S., da Silva T.C., Avanzo J.L., Sinhorini I.L., Guerra J.L., Costa-Pinto F.A., Maiorka P.C., Dagli M.L. Hepatic granulomas induced by Schistosoma mansoni in mice deficient for connexin 43 present lower cell proliferation and higher collagen content. Life Sci. 2007, 80:1228-1235.
87. Orlidge A., D'Amore P.A. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J.Cell Biol. 1987, 105:1455-1462.
88. Oshitari T., Brown D., Roy S. SiRNA strategy against overexpression of extracellular matrix in diabetic retinopathy. Exp. Eye Res. 2005, 81:32-37.
89. Oshitari T., Polewski P., Chadda M., Li A.F., Sato T., Roy S. Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability. Diabetes 2006, 55:86-92.
90. Palenski T.L., Sorenson C.M., Sheibani N. Inflammatory cytokine-specific alterations in retinal endothelial cell function. Microvasc. Res. 2013, 89:57-69.
91. Pan J., Li Q., Zhang L., Jia L., Tang J., Bao Y., Jia W. Serum glycated albumin predicts the progression of diabetic retinopathy-a five year retrospective longitudinal study. J.Diabetes Complicat. 2014.
92. Pankov R., Yamada K.M. Fibronectin at a glance. J.Cell Sci. 2002, 115:3861-3863.
93. Pinheiro A., Roy S. High glucose-induced upregulation of collagen type IV and laminin expression regulates connexin 43 expression in microvascular endothelial cells. 67th American Diabetes Association Conference. Chicago, IL 2007, Abstract # 0838-P.
94. Pkc-Drs-Group, Aiello L.P., Davis M.D., Girach A., Kles K.A., Milton R.C., Sheetz M.J., Vignati L., Zhi X.E. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006, 113:2221-2230.
95. Plouët J., Moro F., Bertagnolli S., Coldeboeuf N., Mazarguil H., Clamens S., Bayard F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J.Biol. Chem. 1997, 272:13390-13396.
96. Portal-Nunez S., Lozano D., de Castro L.F., de Gortazar A.R., Nogues X., Esbrit P. Alterations of the Wnt/beta-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. FEBS Lett. 2010, 584:3095-3100.
97. Poulsom R., Kurkinen M., Prockop D.J., Boot-Handford R.P. Increased steady-state levels of laminin B1 mRNA in kidneys of long-term streptozotocin-diabetic rats. No effect of an aldose reductase inhibitor. J.Biol. Chem. 1988, 263:10072-10076.
98. Powner M.B., Scott A., Zhu M., Munro P.M., Foss A.J., Hageman G.S., Gillies M.C., Fruttiger M. Basement membrane changes in capillaries of the ageing human retina. Br. J. Ophthalmol. 2011, 95:1316-1322.
99. Prunskaite-Hyyrylainen R., Shan J., Railo A., Heinonen K.M., Miinalainen I., Yan W., Shen B., Perreault C., Vainio S.J. Wnt4, a pleiotropic signal for controlling cell polarity, basement membrane integrity, and antimullerian hormone expression during oocyte maturation in the female follicle. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2014, 28:1568-1581.
100. Pugliese G., Pricci F., Romeo G., Pugliese F., Mene P., Giannini S., Cresci B., Galli G., Rotella C.M., Vlassara H., Di Mario U. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997, 46:1881-1887.
101. Rangasamy S., Ljubimov A., Roy S., McGuire P., Das A. Proteinases and integrins in ocular angiogenesis. Therapy for Ocular Angiogenesis 2011, 52-63. Lippincott Williams & Wilkins, Philadelpha, PA. T.F. Arup Das (Ed.).
102. Roth T., Podesta F., Stepp M.A., Boeri D., Lorenzi M. Integrin overexpression induced by high glucose and by human diabetes: potential pathway to cell dysfunction in diabetic microangiopathy. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:9640-9644.
103. Roy R., Zhang B., Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Exp. Cell Res. 2006, 312:608-622.
104. Roy S., Cagliero E., Lorenzi M. Fibronectin overexpression in retinal microvessels of patients with diabetes. Investig. Ophthalmol. Vis. Sci. 1996, 37:258-266.
105. Roy S., Ha J., Trudeau K., Beglova E. Vascular basement membrane thickening in diabetic retinopathy. Curr. Eye Res. 2010, 35:1045-1056.
106. Roy S., Maiello M., Lorenzi M. Increased expression of basement membrane collagen in human diabetic retinopathy. J.Clin. Investig. 1994, 93:438-442.
107. Roy S., Nasser S., Yee M., Graves D.T., Roy S. Along-term siRNA strategy regulates fibronectin overexpression and improves vascular lesions in retinas of diabetic rats. Mol. Vis. 2011, 17:3166-3174.
108. Roy S., Roth T. Proliferative effect of high glucose is modulated by antisense oligonucleotides against fibronectin in rat endothelial cells. Diabetologia 1997, 40:1011-1017.
109. Roy S., Sato T., Paryani G., Kao R. Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes 2003, 52:1229-1234.
110. Sanchez-Lopez A., Cuadros M.A., Calvente R., Tassi M., Marin-Teva J.L., Navascues J. Radial migration of developing microglial cells in quail retina: a confocal microscopy study. Glia 2004, 46:261-273.
111. Sarrazin S., Lamanna W.C., Esko J.D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 2011, 3.
112. Sato T., Haimovici R., Kao R., Li A.F., Roy S. Downregulation of connexin 43 expression by high glucose reduces gap junction activity in microvascular endothelial cells. Diabetes 2002, 51:1565-1571.
113. Sato T., Paryani G., Kao R.S., Li A.F., Roy S. Antisense oligonucleotides modulate high glucose-induced laminin overexpression and cell proliferation: a potential for therapeutic application in diabetic microangiopathy. Antisense Nucleic Acid Drug Dev. 2001, 11:387-394.
114. Schuindt S.H., Oliveira B.C., Pimentel P.M., Resende T.L., Retamal C.A., DaMatta R.A., Seipel D., Arnholdt A.C. Secretion of multi-protein migratory complex induced by Toxoplasma gondii infection in macrophages involves the uPA/uPAR activation system. Vet. Parasitol. 2012, 186:207-215.
115. Si Y.F., Wang J., Guan J., Zhou L., Sheng Y., Zhao J. Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats. Br. J. Pharmacol. 2013, 169:619-631.
116. Simo R., Carrasco E., Garcia-Ramirez M., Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr. Diabetes Rev. 2006, 2:71-98.
117. Singh L.P. Thioredoxin interacting protein (TXNIP) and pathogenesis of diabetic retinopathy. J.Clin. Exp. Ophthalmol. 2013, 4.
118. Arandomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch. Ophthalmol. 1990, 108:1234-1244. Sorbinil-Retinopathy-Trial-Group.
119. Spirin K.S., Saghizadeh M., Lewin S.L., Zardi L., Kenney M.C., Ljubimov A.V. Basement membrane and growth factor gene expression in normal and diabetic human retinas. Curr. Eye Res. 1999, 18:490-499.
120. Spiro M.J., He Q., D'Autilia M.L. Effect of high glucose on formation of extracellular matrix components by cultured rat heart endothelial cells. Diabetologia 1995, 38:430-436.
121. Stenzel D., Lundkvist A., Sauvaget D., Busse M., Graupera M., van der Flier A., Wijelath E.S., Murray J., Sobel M., Costell M., Takahashi S., Fassler R., Yamaguchi Y., Gutmann D.H., Hynes R.O., Gerhardt H. Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development 2011, 138:4451-4463.
122. Stitt A., Gardiner T.A., Alderson N.L., Canning P., Frizzell N., Duffy N., Boyle C., Januszewski A.S., Chachich M., Baynes J.W., Thorpe S.R. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002, 51:2826-2832.
123. Stitt A.W., Anderson H.R., Gardiner T.A., Archer D.B. Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br. J. Ophthalmol. 1994, 78:133-137.
124. Sundaramoorthy M., Meiyappan M., Todd P., Hudson B.G. Crystal structure of NC1 domains. Structural basis for type IV collagen assembly in basement membranes. J.Biol. Chem. 2002, 277:31142-31153.
125. Tanigawa S., Wang H., Yang Y., Sharma N., Tarasova N., Ajima R., Yamaguchi T.P., Rodriguez L.G., Perantoni A.O. Wnt4 induces nephronic tubules in metanephric mesenchyme by a non-canonical mechanism. Dev. Biol. 2011, 352:58-69.
126. Taniyama Y., Griendling K.K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003, 42:1075-1081.
127. Taraboletti G., D'Ascenzo S., Borsotti P., Giavazzi R., Pavan A., Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am. J. Pathol. 2002, 160:673-680.
128. Tarallo S., Beltramo E., Berrone E., Porta M. Human pericyte-endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment. Acta Diabetol. 2012, 49(Suppl.1):S141-S151.
129. Tarr J.M., Kaul K., Chopra M., Kohner E.M., Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013, 2013:343560.
130. Tien T., Barrette K.F., Chronopoulos A., Roy S. Effects of high glucose-induced Cx43 downregulation on occludin and ZO-1 expression and tight junction barrier function in retinal endothelial cells. Investig. Ophthalmol. Vis. Sci. 2013, 54:6518-6525.
131. Tien T., Muto T., Barrette K., Challyandra L., Roy S. Downregulation of Connexin 43 promotes vascular cell loss and excess permeability associated with the development of vascular lesions in the diabetic retina. Mol. Vis. 2014, 20:732-741.
132. To M., Goz A., Camenzind L., Oertle P., Candiello J., Sullivan M., Henrich P.B., Loparic M., Safi F., Eller A., Halfter W. Diabetes-induced morphological, biomechanical, and compositional changes in ocular basement membranes. Exp. Eye Res. 2013, 116:298-307.
133. Tomaselli K.J. Beta 1-integrin-mediated neuronal responses to extracellular matrix proteins. Ann. N. Y. Acad. Sci. 1991, 633:100-104.
134. Tromp A., Hooymans J.M., Barendsen B.C., van Doormaal J.J. The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc. Ophthalmol. Adv. Ophthalmol. 1991, 78:153-159.
135. Trudeau K., Muto T., Roy S. Downregulation of mitochondrial connexin 43 by high glucose triggers mitochondrial shape change and cytochrome C release in retinal endothelial cells. Investig. Ophthalmol. Vis. Sci. 2012, 53:6675-6681.
136. Trudeau K., Roy S., Guo W., Hernandez C., Villarroel M., Simo R., Roy S. Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Investig. Ophthalmol. Vis. Sci. 2011, 52:6348-6354.
137. Tsilibary E.C. Microvascular basement membranes in diabetes mellitus. J.Pathol. 2003, 200:537-546.
138. Uemura A., Kusuhara S., Wiegand S.J., Yu R.T., Nishikawa S. Tlx acts as a proangiogenic switch by regulating extracellular assembly of fibronectin matrices in retinal astrocytes. J.Clin. Investig. 2006, 116:369-377.
139. Valero C., Javierre E., Garcia-Aznar J.M., Gomez-Benito M.J. Acell-regulatory mechanism involving feedback between contraction and tissue formation guides wound healing progression. PloS One 2014, 9:e92774.
140. van der Heyden M.A., Rook M.B., Hermans M.M., Rijksen G., Boonstra J., Defize L.H., Destree O.H. Identification of connexin43 as a functional target for Wnt signalling. J.Cell Sci. 1998, 111(Pt 12):1741-1749.
141. Vempati P., Mac Gabhann F., Popel A.S. Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PloS One 2010, 5:e11860.
142. Verrecchia F., Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J.Investig. Dermatol. 2002, 118:211-215.
143. Waggett A.D., Benjamin M., Ralphs J.R. Connexin 32 and 43 gap junctions differentially modulate tenocyte response to cyclic mechanical load. Eur. J. Cell Biol. 2006, 85:1145-1154.
144. Wang C.Y., Liu H.J., Chen H.J., Lin Y.C., Wang H.H., Hung T.C., Yeh H.I. AGE-BSA down-regulates endothelial connexin43 gap junctions. BMC Cell Biol. 2011, 12:19.
145. Way K.J., Katai N., King G.L. Protein kinase C and the development of diabetic vascular complications. Diabet. Med. J. Br. Diabet. Assoc. 2001, 18:945-959.
146. Wei C.J., Xu X., Lo C.W. Connexins and cell signaling in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20:811-838.
147. Weston B.S., Wahab N.A., Mason R.M. CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. J.Am. Soc. Nephrol. JASN 2003, 14:601-610.
148. Winkler J.L., Kedees M.H., Guz Y., Teitelman G. Inhibition of connective tissue growth factor by small interfering ribonucleic acid prevents increase in extracellular matrix molecules in a rodent model of diabetic retinopathy. Mol. Vis. 2012, 18:874-886.
149. Wright J.A., Richards T., Becker D.L. Connexins and diabetes. Cardiol. Res. Pract. 2012, 2012:496904.
150. Wu Y., Feng B., Chen S., Chakrabarti S. ERK5 Regulates glucose-induced increased fibronectin production in the endothelial cells and in the retina in diabetes. Invest. Ophthalmol. Vis. Sci. 2012, 53:8405-8413.
151. Xu X., Li Z., Luo D., Huang Y., Zhu J., Wang X., Hu H., Patrick C.P. Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefe's Arch. Clin. Exp. Ophthalmol. Albrecht von Graefes Arch. klin. Exp. Ophthalmol. 2003, 241:56-62.
152. Yang H.W., Chen X.L., Liu Z.L., Liu J., Bu L.M. CTGFsiRNA ameliorates retinal cells apoptosis in streptozotocin-induced diabetic rats. Int. J. Ophthalmol. 2010, 3:120-124.
153. Yoshimura T., Sonoda K.H., Sugahara M., Mochizuki Y., Enaida H., Oshima Y., Ueno A., Hata Y., Yoshida H., Ishibashi T. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PloS One 2009, 4:e8158.
154. You J.J., Yang C.H., Yang C.M., Chen M.S. Cyr61 induces the expression of monocyte chemoattractant protein-1 via the integrin alphanubeta3, FAK, PI3K/Akt, and NF-kappaB pathways in retinal vascular endothelial cells. Cell. Signal. 2014, 26:133-140.
155. Yurchenco P.D., Patton B.L. Developmental and pathogenic mechanisms of basement membrane assembly. Curr. Pharm. Des. 2009, 15:1277-1294.